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A B S T R A C T
Purpose: To compare hospital service use before and after VNS therapy implantation in a sample of drug-
resistant people with epilepsy.
Method: The before and after study was performed using anonymised Hospital Episode Statistics (HES)
data from one year before to 3 years after implantation in 321 patients from data collected between April
2009 to July 2011. Episodes relating to out-patient clinic, Accident and Emergency (A&E) department
attendance, hospital admissions and length of stay were collected and compared. Descriptive statistics
are used to summarise patient demographics, patient pathways and resource usage before and after VNS
implantation. Means and proportions were reported on continuous variables, proportion and frequency
on categorical variables. Trends of activity over time were determined using before and after VNS
comparisons and tested with the Wilcoxon Signed-rank (WSR) test.
Results: The summary statistics indicate a drop in resource use in terms of in-patient bed-days (21%
decrease), elective in-patient episodes (7% decrease) and non-elective in-patient episodes (14%
decrease). There was an increase in the quarterly average out-patient appointments by 12%. The A&E
attendance outcome recorded a mean increase in quarterly attendances of 9% but a slight decrease when
subject to a signed rank test. These contradictory results should therefore be treated with caution.
Conclusion: VNS Therapy may be associated with an overall reduction in health service resource use.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Patients with drug resistant epilepsy (DRE) may be referred to
an Epilepsy Surgery Programme but some are not suitable for
resective surgery for their epilepsy [1–3]. This is due to a number of
factors including poor localisation of lesions, the location of
seizures, and co-morbidities [4]. The palliative procedures
available for such cases include corpus callosotomy, stimulation
of the vagus nerve, deep brain stimulation and transcranial
magnetic stimulation. Of these palliative procedures Vagus Nerve
Stimulation (VNS Therapy1, Cyberonics Inc. Houston TX, USA) has
gained widespread popularity and in excess of 80,000 devices
world-wide have been implanted in DRE patients in the last
20 years. Vagus nerve stimulation (VNS) can reduce seizures in* Corresponding author. Tel.: +353 0 21 490 1572.
E-mail address: henry.smithson@ucc.ie (W.H. Smithson).
http://dx.doi.org/10.1016/j.seizure.2015.11.002
1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights resome patients with DRE [5] and yet there is a variable referral rate
for assessment for VNS therapy.
The pattern of under-referral is reported internationally with
referral for surgical assessment in Sweden estimated to be
underused in individuals with focal drug resistant epilepsy
[6]. In the USA trends in lobectomy between 1990 and 2008 sug-
gests underutilisation despite a doubling in hospitalisations in that
period for DRE [7]. A retrospective study suggests that referral may
be increasing in line with recommendations from the American
Academy of Neurology (AAN) [8]. A survey of neurologists in the
UK highlighted an overall reduction of adult surgical treatments
from a total of 578 in 2000 to 472 in 2011. There was an almost 50%
drop in lesional resection with an increase in neuromodulatory
procedures from 156 to 230 [9]. In children the picture may be
different with a single centre study from Holland showing an
increase in resective surgery each year from 1990 to 2011 [10].
The pattern of VNS use in England is interesting in that while
the number of resective surgery procedures fell in the ﬁrst decadeserved.
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adults increased [9]. VNS now accounts for over half of epilepsy
surgery procedures (55.2%) of which 69% were performed in 6 large
university centres [9]. In England and Wales VNS implantation has
risen from 148 new implants in 2009 to 246 in 2013 with some
centres implanting over 50 devices in this period and some less
than 10 devices. There was also an associated increase in battery
replacements with 81 in 2009 and 302 in 2013. This is in line with
guidance in the UK [11] that recommend VNS as a treatment for
both focal and generalised seizures in children and adults. In the
USA guidance recommends consideration of VNS for Lennox
Gaustaut Syndrome (LGS) because the responder rates for patients
with LGS appears not to differ from the general population of
patients with drug resistant epilepsy [12].
The factors affecting the variable referral rate for VNS
assessment are not known. Clearly, the therapy is effective in
the majority of recipients although some patients do not respond
[5,13,14] but treatment costs may be a factor.
The costs of assessment and implantation are signiﬁcant but in
the USA, the device costs are balanced by a reduction in health care
utilisation costs with the breakeven point being after 18 months of
therapy overall but with a more rapid break-even point of
12 months for 12–18 year olds [15,16]. It is not clear whether
this picture would transfer from the American mixed model health
system where health expenditure costs 16.9% of GDP in 2010 to the
UK system where there is a cost contained single tier taxation
based Beveridge health system [17] costing 9.3% of GDP [18].
With the increasing use of VNS Therapy in the UK, It is also
timely to explore the clinical impact of VNS given the relationship
of seizure frequency to hospital utilisation [19] and the evidence
relating to seizure reduction with VNS Therapy [7,15,20]. The NHS
Commissioning Board, recognising that ‘patients with refractory
epilepsy require more out-patient clinic time, combination
therapy (often with newer, expensive anti-epileptic drugs) and
hospitalisation’ developed a commissioning policy for VNS to
ensure more equitable provision of services [21]. This policy should
be welcomed by commissioners who are aware of the increasing
burden of non-elective activity on the NHS [22–24] reported by
NHS England as 5.9% more episodes of unscheduled care in 2012–
2013, than in 2009–2010; an increased number of acute
admissions putting pressure on bed occupancy with 10.6% more
emergency admissions in 2012–2013 than in 2009–2010 [25] and
a reported 12% increase in Accident and Emergency (A&E)
attendance in the last decade [26]. This study assessed the effect
of VNS Therapy on hospital utilisation.
2. Methods
A before and after health utilisation study was performed on
321 anonymised patients who received VNS Therapy in NHS
hospitals in the UK between April 2009 and July 2011 of which
nearly half (n = 123) were implanted in 3 centres (Bristol, Kings
College London and Shefﬁeld).Fig. 1. StudyHospital Episode Statistics (HES) data of elective and non-
elective in-patient admissions and out-patient appointments and
also A&E department attendances and disposal were analysed in
the secondary care setting, activity 12 months prior and 36 months
following VNS implantation were compared. Per-quarter average
resource use was evaluated in order to provide a normalised
measure of resource use for comparison across unequal windows
of observation (see Fig. 1).
Patients were identiﬁed for inclusion in the sample using a
combination of diagnosis and intervention codes. To determine
that the patient had undergone VNS implantation to treat epilepsy,
they had to have an in-patient or out-patient record between April
2006 and July 2014 containing diagnosis codes G40 ‘Epilepsy’ and/
or G41 ‘Status epilepticus’. April 2006 was the earliest point from
which patient data was available, and so data from this point was
included in the identiﬁcation window to ensure the largest pool of
epilepsy patients possible.
In addition they also had to have an in-patient or out-patient
record between April 2009 and July 2011 containing procedure
code A33.1 ‘Introduction of neurostimulator into cranial nerve’ and
the site of intervention code Z04.4 ‘Vagus nerve (x)’. Transcutane-
ous stimulator (OPCS code Y90.1) was not included in the study
sample.
Patients with a VNS implantation date between 1st April
2009 and 31st July 2011 were selected in order to ensure that all
patients had at least the required observation period for
comparison (one year prior and three years post VNS implanta-
tion). Reliable A&E data is available from 1st April 2008 so an
inclusion date of 1st April 2009 was required in order to allow all
patients at least four quarters of reliable A&E attendance data.
Patient resource utilisation was calculated retrospectively and
normalised to average (mean) visits/days per quarter. This allows
fair comparison of the pre-VNS of 12 months and post-VNS period
of 36 months, taking into account the unequal window of
observation in the two periods. Resource use before and after
VNS was identiﬁed outside of the episode of implantation, so
resource use attributed to either the ‘before’ or ‘after’ intervention
period did not include the in-patient episode in which the patient
received the implant. To match the American study [13], each
patient’s observation period extended from the index date until
removal of the device, death or end of the study period (maximum
3 years of follow-up), whichever occurred ﬁrst.
3. Data analysis
Descriptive statistics were used to summarise patient demo-
graphics, patient pathways, and VNS usage and to assess resource
use comparing the before and after VNS periods. Means and
proportions were reported on continuous variables, proportion
and frequency on categorical variables. Trends of activity over time
were determined comparing the average quarterly resource use
before VNS and quarterly resource use data following VNS.
This trend data was subsequently tested using the Wilcoxon design.
Table 1
Direction of the shift in resource use across the outcome variables featured in descriptive statistics, as measure by the Wilcoxon signed-rank test.
Quarter following VNS Bed-days p-Value Elective p-Value Non-elective p-Value Outpatient p-Value A&E p-Value
1 Decrease 0.00 Decrease 0.00 Decrease 0.00 Increase 0.00 Decrease 0.00
2 Decrease 0.00 Decrease 0.00 Decrease 0.00 Increase 0.00 Decrease 0.01
3 Decrease 0.00 Decrease 0.00 Decrease 0.00 Increase 0.04 Decrease 0.00
4 Decrease 0.00 Decrease 0.00 Decrease 0.00 Increase 0.11 Decrease 0.00
5 Decrease 0.00 Decrease 0.00 Decrease 0.00 Increase 0.89 Decrease 0.00
6 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.39 Decrease 0.01
7 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.24 Decrease 0.03
8 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.01 Decrease 0.02
9 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.03 Decrease 0.00
10 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.07
11 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.06 Decrease 0.02
12 Decrease 0.00 Decrease 0.00 Decrease 0.00 Decrease 0.04 Decrease 0.01
Note: p-Values are from the Wilcoxon signed-rank test performed. If the p-Value is <0.05 we can reject the null hypothesis that the change in resource use was equal 0, when
comparing before and after VNS implantation.
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equivalent to the t-test, and was used to test for statistically
signiﬁcant differences in resource use following VNS, relative to a
baseline of average (quarterly) resource use prior to VNS in terms
of in-patient bed-days, elective in-patient, non-elective in-patient,
out-patient and A&E visits (Table 1). The WSR test provides an
alternative measure of change across the before and after VNS
periods that is not inﬂuenced by extreme outliers that may be
captured in the data. The WSR was used in order to evaluate the
sensitivity of outputs from descriptive statistics to the assumption
of a normal distribution in outcome data.
4. Results
The study population of 321 VNS users was 52% male with an
age range from 2 to 75 and a mean age of 27.8 years (n = 320 with
one missing value) with 118 patients age 19 years or less, 117 age
20–39 years, 77 age between 40 and 59 years and 9 patients
age 60 years and older. The ﬁrst VNS implantation was recorded
1st April 2009 and the last recorded 29th July 2011 giving a total of
17,317 observations of which there were 4019 observations
before VNS and 12,997 after. Before and after VNS elective and
non-elective episodes per quarter were compared for in-patient
bed days, out-patient appointments and A&E attendances
(Table 2). The summary statistics, based on mean quarterly
utilisation, indicate that there has been a drop in resource use
when comparing the before and after VNS periods in terms of
in-patient bed-days (21% decrease), elective in-patient episodes
(7% decrease) and non-elective in-patient episodes (14% decrease).
There was an increase in the quarterly average out-patient
appointments by 12% possibly due to routine post-surgical
follow-up and device management.Table 2
Summary statistics: change in average quarterly resource use following VNS
implant.
Total resource use (any reason) Before VNS
(12-month
quarterly
average)
After VNS
(36-month
quarterly
average)
Change
following
VNSc (%)
Bed-daysa 1.34 1.06 21
Inpatient episodes (elective)b 0.20 0.18 7
Inpatient episodes (non-elective) 0.31 0.26 14
Outpatient appointments 2.27 2.54 12
A&E attendances 0.40 0.43 9
a Within admission overlap in bed-days accounted for.
b Inclusive of day cases and elective inpatient admissions.
c Percentage change in mean quarterly resource use when comparing before and
after VNS implant.A&E attendance was found to be inﬂuenced by a small number
of patients non-responsive to VNS, who experienced a high volume
of A&E attendance in the follow up period resulting in an increase
reported from the summary statistics. Further investigation into
the A&E outcome variable revealed there is uncertainty in results
shown from descriptive summary statistics alone for this outcome,
given a skewed distribution of A&E attendances.
The clinical codes reported most commonly by 4 frequent
attenders of A&E were examined and are included later.
The results of the WSR test demonstrated a statistically
signiﬁcant (p < 0.05) decline in resource use comparing before
and after VNS implant in all 12 quarters following intervention
across in-patient bed-days, non-elective in-patient episodes and
elective in-patient episodes. The WSR test reported a statistically
signiﬁcant decline in A&E attendance in all quarters following VNS
with the exception of quarter 10 which reported a decline,
however failed to reach signiﬁcance level p < 0.05 (p-value 0.07).
The out-patient appointments results showed increase in resource
use following VNS until quarter 8 where we see a statistically
signiﬁcant decline (Table 1).
4.1. In-patient admission data
Episodic data collected from in-patient spells (the duration of
in-patient care) show 611 observed episodes before VNS and
1640 episodes after (mean 152.8 and 136.7 per quarter,
respectively). 374 non-elective episodes were captured before
VNS and 954 after (mean 93.5 and 79.5 per quarter, respectively). A
small decrease was seen in elective episodes also, with 237 epi-
sodes before VNS and 686 after (mean 59.25 and 57.17 per quarter,
respectively). There was a reduction in mean quarterly in-patient
bed-days by 21% from a quarterly average of 1.34 before VNS to a
quarterly average of 1.06 after.
4.2. Elective activity
There were 686 elective admissions after VNS with a mean of
57 per quarter. The primary diagnoses for the elective admissions
other than codes for generalised or localisation-related epilepsy
was for holiday relief care. There was a shift in the ratio of elective
to non-elective in-patient episodes following VNS, with an increase
in elective and an equivalent decrease in non-elective episodes.
4.3. Non-elective activity
There were 954 non-elective in-patient episodes after VNS
(mean 80 per quarter) with a decrease in mean per-quarter non-
elective episodes from 0.31 before VNS to 0.26 after (Fig. 2). There
was a modest rise in the ﬁrst 6 months after implant and then a
Fig. 2. Percent change in non-elective in-patient episodes when comparing before VNS quarterly average with quarters following VNS.
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available data, the majority of primary diagnostic codes for the
non-elective episodes were related to epilepsy including 10 epi-
sodes coded as status epilepticus.
4.4. Out-patient appointments
Out-patient coding is also incomplete in 95% of appointments.
The management of device settings and duty cycles after device
implantation may require some additional appointments. The
quarterly trend data indicate that this increase ﬂattens after
18 months following VNS to a level just below the mean
appointment frequency across the before VNS period. The mean
quarterly number of appointments over the study period is
2.27 appointments before and 2.54 appointments after VNS. The
majority (70%) of appointments after VNS were with epilepsy
related specialities including neurology, neurosurgery, paediatric
neurology or paediatrics and around 10% of appointments were
with trauma/orthopaedics or mental illness specialists.
The mean number of quarterly out-patient appointments in the
12 quarters following implant showed a signiﬁcant rise in activity
particularly in the ﬁrst 3 months. The increase continues for
3 quarters after VNS with the activity returning to levels seen
before VNS at quarter 6, with a small decrease recordedFig. 3. Number of VNS maintenance procedbetween quarter 6 and quarter 12. When the activity for device
maintenance was plotted for the 3 years following implant, it
shows a gradual reduction from 26 episodes in the ﬁrst year to
10 episodes in the second year with a rise in the 3rd year to
25 episodes (Fig. 3). There were 8 devices removed, one in the ﬁrst
year, 4 in the second year and 3 in the third year. No information
was recorded about the reason for removal.
4.5. Accident & Emergency (A&E) Department attendance
The number of A&E attendances recorded before VNS was 506
(mean 127 per quarter) and 1635 after (mean 137 per quarter). In
the period before VNS one patient attended 10 times in a single
quarter and another patient attended 9 times within a quarter. In
the period after VNS, there were patients who attended between
10 and 16 times in a single quarter. The majority of patients did not
visit A&E, with between 72 and 77% not attending each quarter
following implant. The A&E attendance ﬁgures were therefore
skewed by a small number of frequent attenders with 3% or less
attending A&E 4 times or more a quarter.
When the A&E data was tested using the Wilcoxon Sign-Rank
(WSR) test the results showed a decrease in A&E resource use in
each quarter following implant when compared against the
average quarterly attendance before VNS, with only quarterures recorded following VNS implant.
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WSR test results indicated a decrease in resource use, but this is
contradictory to what we ﬁnd looking at the descriptive statistics
alone and is likely a good indicator that the mean is not an effective
measure of average resource use for A&E attendance outcome.
Given the skewed nature of the A&E outcome, and the contradic-
tion across various statistical measures of average resource use, we
approach the results of A&E activity with caution.
Aggregated numbers of attendances in the 3 years after VNS
showed that only 3 patients attended more than 35 times in the
3 years after VNS and one outlier attended 94 times. The
diagnostic codes of these 4 most frequent attenders were
examined.
The ﬁrst patient attended A&E a total of 94 times in the 3 years
after implant. The primary diagnostic codes for the visits showed
that in over half the visits, the diagnosis was ‘not classiﬁable’, only
20% coded as ‘central nervous system conditions–epilepsy’ with
25% coded as ‘other non-epilepsy’, ‘psychiatric conditions’, and
‘dissociative (conversion) disorders’. This suggests that this patient
experiences refractory seizures of a non-epileptic origin and so
would not respond to the device.
The next patient attended A&E 7 times in a single quarter after
VNS and the primary diagnoses included ‘gastrointestinal condi-
tions-acute abdominal pain’ and gastrointestinal conditions–
other’, ‘urological conditions (including cystitis)’ and ‘social
problem’. In the 19 diagnostic observation codes, only 2 stated
‘central nervous system–epilepsy’ and so it appears that epilepsy
was not the clinical problem in the 7 A&E visits.
The 3rd frequent attender had diagnostic codes suggesting
severe trauma including lacerations, burns and dislocation/
fractures. The 4th case attended with the majority of codes being
related to epilepsy. It is possible that these two cases are VNS non-
responders.
An estimate of the severity of injury causing A&E attendance
was made by assigning trauma codes recorded to ‘serious’ or ‘non-
serious’ categories for comparison over the before and after VNS
periods (Fig. 4). A&E attendances with a discernible diagnosis were
included, with 571 observations before VNS (mean 93 per quarter)
and 1429 observations after (mean 61 per quarter).Fig. 4. Proportion of codes that were contained within the ‘Serious traThe codes considered ‘Serious trauma’ were head injury,
fracture, burns/scalds, laceration and the non-serious or ‘Mild
trauma’ codes were sprain/ligament injury, contusion, soft tissue
inﬂammation. The number of ‘Serious trauma’ codes demonstrated
a reduction from 26% to 18% of observations when comparing
before and after VNS, respectively. The disposal codes of patients in
A&E were compared before (1087 observations, mean 272 per
quarter) and after (2308 observations, mean 193 per quarter) VNS
implant. There was little difference in disposal pathways with over
half being discharged without follow-up or follow-up by the
general practitioner and around a third of patients being
‘admitted’.
5. Discussion
The Hospital Episode Statistics dataset from the NHS in England
captures complete hospital activity for all patients treated with a
VNS Therapy device and provides details of both elective and non-
elective episodes. VNS Therapy appears to reduce the number of
episodes of unscheduled admission and bed days but the impact on
A&E attendance is equivocal. It would also appear to result in
increased outpatient activity. Inpatient data shows a change in the
ratio of elective to non-elective admissions with a decrease in the
proportion of non-elective admissions. Planned activity beneﬁts
both the patient and the health service and is an important criteria
when commissioning health services.
While the HES dataset gives full episodic data, the clinical
coding was often incomplete and so the reasons for the reduction
in resource use after implant are uncertain. However, the reduction
in bed days and serious trauma may be a surrogate measure for
reduced seizure severity.
The A&E data were skewed with the majority of patients (over
70%) not attending and less than 3% attending 4 times or more per
quarter. The mean attendance rose after VNS and the clinical codes
of the most frequent attenders suggested attendance was due to
conditions in part not related to epilepsy. Non-parametric analysis
suggests that attendance may reduce after implant but these
results should be treated with caution. Clinical coding allowed A&E
attendance to be ranked as due to either ‘serious’ or ‘non-serious’uma’ and ‘Mild trauma’ categories assigned, before and after VNS.
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treatment. The WSR test provides an alternative measure of change
across the before and after VNS periods that is not inﬂuenced by
extreme outliers that may be captured in the data. An analysis of
means after removal of outliers was considered but there was no
obvious cut point and it is difﬁcult to avoid bias if data was
manipulated in this way. The national trend in overall A&E activity
in England during the study period showed an increase and this
was not factored into the before and after analysis.
Outpatient activity increased after implant and this is to be
expected due to the programming and monitoring of the devices.
The management of the device is tailored to the patient and
guidance recommends between 6 to 8 additional outpatient clinic
attendances for individualisation of the settings over the ﬁrst
12 months following implantation [18]. These visits are assumed
to be over and above the bi-annual visits that every patient with
epilepsy would routinely attend each year. In the UK, device
programming is done by members of the multi-disciplinary team
[21]. This is a signiﬁcant workload and has to be planned carefully
using the expertise found in specialist units. VNS Therapy may be
effective for some patients but with the marginal hospital activity
beneﬁts after implant, it is important to select patients most likely
to respond to the treatment and this selection may be best
performed in centres with a dedicated Multi-Disciplinary Team.
6. Conclusion
This study compares hospital utilisation in patients with DRE
before and after initiation of VNS Therapy in an English sample
using data for 1 year before and 3 years after implant. There is a
small decrease in some elective and non-elective episodes but the
most noticeable changes are in a reduction of episodes of
unscheduled care and length of hospital stay. There is an increase
in mean A&E attendance after implant but the sample is skewed by
a small number of frequent attenders and after adjustment there
may be a small decrease in attendance after VNS. There is a
decrease in serious trauma after VNS. There is an increase in
outpatient episodes associated with device programming.
The study has limitations. The clinical coding was inadequate
and did not allow for a detailed analysis of either out-patient or in-
patient episodes. The uncertainty around the statistical tests
reported on A&E data means that although analysis may show a
reduction in activity the results should be treated with caution.
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